Cancer Chemotherapy and Pharmacology

, Volume 30, Supplement 1, pp S90–S94 | Cite as

The use of adriamycin and its derivatives in the treatment of prostatic cancer

  • D. W. W. Newling
Session III: State of the Art in Urinary Tract Tumors Prostatic Cancer, Adriamycin


Adriamycin and the other anthracyclines are amongst the most effective cytotoxic agents at the clinician's disposal. At least one of the reasons for their efficacy is the large number of mechanisms by which they can induce potentially lethal damage in a dividing malignant cell. Adriamycin and epirubicin are amongst the more effective agents in advanced hormone-independent prostate cancer. When given in full doses, they produce a reasonable number of objective as well as subjective responses, but the resultant toxicity precludes their use at high dose in many patients. In a number of well-documented studies, lower doses of these agents have yielded useful subjective responses with minimal toxicity.


Prostate Cancer Cancer Research Malignant Cell Anthracyclines Adriamycin 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Burk K (1989) Weekly chemotherapeutic regimen in metastatic prostate cancer. In: Murphy GPM, Khowy S (eds) Therapeutic progress in urological cancers. Alan R. Liss, New York, pp 261–275Google Scholar
  2. 2.
    Burk K, Schultze-Seeman W, Derise W (1987) A new concept of chemotherapy in hormone resistant progressive carcinoma of the prostate: 4-epirubicin 40 mg weekly. J Urol 137: 257AGoogle Scholar
  3. 3.
    Burk K, Schultze-Seeman W, Jonas D, Rodeck G (1989) Weekly epirubicin in patients with hormone refractory prostatic cancer. A two-year follow-up. In: Ratliff T, Murphy GPM, Khowy S (eds) Therapeutic progress in urological cancers. Alan R. Liss, New York, pp 277–286Google Scholar
  4. 4.
    Drago J (1987) Chemotherapy of prostate cancer. In: Catalona J (ed) Urological oncology. Alan R. Liss, New York, pp 51–78Google Scholar
  5. 5.
    Fosså SD, Urnes T, Kaalhus O (1987) Weekly low-dose Adriamycin in hormone-resistant metastatic cancer of the prostate. Scand J Urol Nephrol 21: 13Google Scholar
  6. 6.
    Francini G, Nami R, Bianchini C, Gennari C (1987) Chemotherapy of advanced prostatic cancer with epirubicin. Eur J Cancer Clin Oncol 23: 1240Google Scholar
  7. 7.
    Isaacs JT (1986) New principles in the management of metastatic prostatic cancer. In: Das Prostatakarzinom zwischen Hormontherapie und Zytostase. Medical Trends, Solingen, p 5027Google Scholar
  8. 8.
    Jones WG, Fosså SD, Bono AV, Klijn JGM, de Pauw M, Sylvester R (1987) European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep 71: 1317Google Scholar
  9. 9.
    Labrie F, Luthy I, Veilleux R, Simard J, Belanger A, Dupont A (1987) New concepts on the androgen sensitivity of prostate cancer. Prog Clin Biol Res 243A: 145Google Scholar
  10. 10.
    MacNeal JE (1979) New Morphologic Finding reterans to the Origin and Evolution of Carcinoma of the Prostate and B.P.H. UICC technical report series, vol. 48; p 24Google Scholar
  11. 11.
    Murphy GP, Slack NH, the National Prostatic Cancer Project (1984) Current status of the National Prostatic Cancer Project treatment protocols. In: Controlled clinical trials in urologic oncology. Raven Press, New York, p 119Google Scholar
  12. 12.
    Newling DWW, Fosså SD, Thun U, Kurth RH (1992) Estramustine vs mitomycin C in hormone refractory prostate cancer. Preliminary results of an EORTC phase III study. J Clin Endocrinol (in press)Google Scholar
  13. 13.
    Robinson MRG, Richards B, Newling D, Smith PH (1984) Weekly low-dose Adriamycin in advanced disseminated carcinoma of the prostate: a palliative approach. In: Controlled clinical trials in urologic oncology. Raven Press, New York, p 187Google Scholar
  14. 14.
    Torti FM, Aston D, Lum BL, Kohler M, Williams R, Spaulding JT, Shortliffe L, Freiha FS (1983) Weekly doxorubicin in endocrine-refractory carcinoma of the prostate. J Clin Oncol 1: 477Google Scholar
  15. 15.
    Torti FM, Bristow MR, Howes AE, Aston D, Stockdale FE, Carter SK, Kohler M, Brown BW Jr, Billingham ME (1983) Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med 99: 745Google Scholar

Copyright information

© Springer-Verlag 1992

Authors and Affiliations

  • D. W. W. Newling
    • 1
  1. 1.Dept. of UrologyFree University HospitalAmsterdamThe Netherlands

Personalised recommendations